While all pharma companies get classified into one sector they are very different at molecular level. Each company has its own operating matrix, some are more dependent on what USFDA does both India and US. While some are more impacted by what is happening in China, which to the surprise of many is one of the biggest manufacturing bases of Active pharmaceutical ingredient which is commonly called API. After a long period of time some tailwinds are emerging for a large number of pharma companies. Will they sustain?
